NervGen Pharma Corp

NervGen Pharma Corp is a clinical-stage biotechnology company, not an asset manager or family office. It develops therapies for nervous system damage, with a lead candidate NVG-291 targeting spinal cord injury and multiple sclerosis. The firm funds operations through public equity markets and potential licensing deals.

No. NervGen Pharma Corp is a publicly traded company (TSX: NGEN) focused on drug development. It does not operate as a family office, asset manager, or investment firm. Its shareholders include public market investors, not a single family or external allocators.

NervGen has advanced NVG-291 into Phase 1 clinical trials, with a Phase 1b/2a study in spinal cord injury initiated in 2021. The company has published preclinical data in peer-reviewed journals, but no regulatory approvals have been secured. The firm's pipeline also includes programs in multiple sclerosis and Alzheimer's disease.

NervGen Pharma Corp was founded by a group of scientists and executives including Dr. Jerry Silver, a professor at Case Western Reserve University, and other biotech professionals. The company's executive team is not structured around a single family or personal fortune.

NervGen is headquartered in Vancouver, Canada, with its scientific collaborations spanning North American research centers. The company is listed on the TSX Venture Exchange and does not operate additional investment offices in other regions.